e-learning
resources
Stockholm 2002
Tuesday 17.09.2002
Community- and hospital-acquired pneumonias: inflammatory mechanisms, epidemiology and therapy
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
D-Dimer as a marker of fibrinolytic activity in complicated parapneumonic effusions and empyema
E. Laserna, J. L. López-Campos, B. Romero, F. Rodríguez-Panadero, E. Barrot (Sevilla, Spain)
Source:
Annual Congress 2002 - Community- and hospital-acquired pneumonias: inflammatory mechanisms, epidemiology and therapy
Session:
Community- and hospital-acquired pneumonias: inflammatory mechanisms, epidemiology and therapy
Session type:
Poster Discussion
Number:
2669
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
E. Laserna, J. L. López-Campos, B. Romero, F. Rodríguez-Panadero, E. Barrot (Sevilla, Spain). D-Dimer as a marker of fibrinolytic activity in complicated parapneumonic effusions and empyema. Eur Respir J 2002; 20: Suppl. 38, 2669
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
To code or not to code chronic pulmonary aspergillosis associated malnutrition in PMSI database: that is the problem…
Related content which might interest you:
Pleural-fluid myeloperoxidase in complicated and noncomplicated parapneumonic pleural effusions
Source: Eur Respir J 2002; 19: 320-325
Year: 2002
Efficacy of intrapleural streptokinase use in complicated parapneumonic pleural effusions and empyema
Source: Annual Congress 2008 - Pleural effusion
Year: 2008
Pleural fluid C-reactive protein concentration in discriminating uncomplicated from complicated parapneumonic pleural effusion
Source: Annual Congress 2012 - Scores, biomarkers and risk factors in respiratory infections
Year: 2012
Role of C-reactive protein in discriminating complicated and uncomplicated parapneumonic effusion from malignant and tuberculous pleural effusion
Source: Virtual Congress 2021 – Clinical problems associated with cough, pleura and respiratory health status
Year: 2021
Procalcitonin in pleural fluid: A new tool for the diagnosis of empyema and parapneumonic pleural effusions?
Source: Annual Congress 2011 - New aspects in prevention and treatment of community-acquired pneumonia and lower respiratory tract infections
Year: 2011
Parapneumonic effusion and empyema
Source: Respipedia Article
Year: 2017
Treatment results of patients with complicated parapneumonic effusion and empyema
Source: Eur Respir J 2002; 20: Suppl. 38, 358s
Year: 2002
Interelukin-17A is elevated in parapneumonic pleural effusions and is associated with neutrophils and VEGF
Source: Eur Respir J 2006; 28: Suppl. 50, 551s
Year: 2006
Pleural fluid IL-6 levels in the identification of the complicated parapneumonic pleural effusion
Source: Annual Congress 2008 - Pleural effusion
Year: 2008
Respiratory functional status after intrapleural t-PA administration for complicated parapneumonic effusions
Source: Annual Congress 2012 - Viral infections and rare respiratory infections
Year: 2012
Prognostic features of residual pleural thickening in parapneumonic pleural effusions
Source: Eur Respir J 2003; 21: 952-955
Year: 2003
Update on the management of parapneumonic pleural effusions
Source: Virtual Congress 2021 – Spanish/Portuguese programme 2021
Year: 2021
Late period pulmonary functions of the patients who were treated for parapneumonic effusion and empyema
Source: Eur Respir J 2006; 28: Suppl. 50, 488s
Year: 2006
Treatment of parapneumonic pleural effusion and empyema: conservative view
Source: ISSN=1025-448x, ISBN=1-904097-33-2, page=199
Year: 2004
Management of parapneumonic effusion and empyema in children
Source: Eur Respir J 2002; 20: Suppl. 38, 589s
Year: 2002
Diagnostic value of C-reactive protein in discrimination between complicated and uncomplicated parapneumonic effusion
Source: International Congress 2019 – Clinical problems
Year: 2019
Serum C-reactive protein levels predict the need for surgical intervention in patients with empyema/complicated parapneumonic pleural effusions
Source: International Congress 2019 – Pleural infection and complicated pneumonia
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept